Non-Adaptive MR-Guided Radiotherapy for Prostate SBRT: Less Time, Equal Results

Non-Adaptive MR-Guided Radiotherapy for Prostate SBRT: Less Time, Equal Results

Background: The use of stereotactic body radiation therapy (SBRT) is widely utilized for treatment of localized prostate cancer. Magnetic-resonance-guided radiotherapy (MRgRT) was introduced in 2014 and has recently been implemented in SBRT for prostate cancer as it provides an opportunity for small...

Full description

Bibliographic Details
Main Authors:	Maria L. Sandoval, Irini Youssef, Kujtim Latifi, G. Daniel Grass, Javier Torres-Roca, Stephen Rosenberg, Kosj Yamoah, Peter A. Johnstone
Format:	Article
Language:	English
Published:	MDPI AG 2021-07-01
Series:	Journal of Clinical Medicine
Subjects:	prostate MR-guided SBRT non-adaptive
Online Access:	https://www.mdpi.com/2077-0383/10/15/3396

Similar Items

Intrafractional stability of MR-guided online adaptive SBRT for prostate cancer
by: J. Schaule, et al.
Published: (2021-09-01)

The role of online MR-guided multi-fraction stereotactic ablative radiotherapy in lung tumours
by: Svenja Hering, et al.
Published: (2024-03-01)

Feasibility of MR-guided ultrahypofractionated radiotherapy in 5, 2 or 1 fractions for prostate cancer
by: Jonathan Mohajer, et al.
Published: (2021-01-01)

Feasibility and Early Clinical Experience of Online Adaptive MR-Guided Radiotherapy of Liver Tumors
by: Paul Rogowski, et al.
Published: (2021-03-01)

MR-Guided Radiotherapy for Prostate Cancer
by: Boris R. Tocco, et al.
Published: (2020-12-01)

Online adaptive planning for prostate stereotactic body radiotherapy using a 1.5 Tesla magnetic resonance imaging-guided linear accelerator
by: Jinzhong Yang, et al.
Published: (2021-01-01)

On-line adaptive and real-time intrafraction motion management of spine-SBRT on an MR-linac
by: Justine M. Cunningham, et al.
Published: (2022-08-01)

MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial
by: P. Hoegen, et al.
Published: (2022-03-01)

Operating procedures, risk management and challenges during implementation of adaptive and non-adaptive MR-guided radiotherapy: 1-year single-center experience
by: Helena Isabel Garcia Schüler, et al.
Published: (2021-11-01)

Online Magnetic Resonance-Guided Radiotherapy (oMRgRT) for Gynecological Cancers
by: Lorraine Portelance, et al.
Published: (2021-08-01)

1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment
by: Filippo Alongi, et al.
Published: (2020-03-01)

Dosimetric Benefit of Adaptive Magnetic Resonance-Guided Stereotactic Body Radiotherapy of Liver Metastases
by: Fabian Weykamp, et al.
Published: (2022-12-01)

Prostate Fiducial Marker Placement in Patients on Anticoagulation: Feasibility Prior to Prostate SBRT
by: Michelle Iocolano, et al.
Published: (2020-02-01)

Impact of intrafraction changes in delivered dose of the day for prostate cancer patients treated with stereotactic body radiotherapy via MR-Linac
by: Jennifer Dang, et al.
Published: (2022-09-01)

1.5 T MR-Guided Daily Adapted SBRT on Lymph Node Oligometastases from Prostate Cancer
by: Luca Nicosia, et al.
Published: (2022-11-01)

Stereotactic MRI-guided radiation therapy for localized prostate cancer (SMILE): a prospective, multicentric phase-II-trial
by: J. Ristau, et al.
Published: (2022-04-01)

Stereotactic body radiotherapy of central lung tumours using a 1.5 T MR-linac: First clinical experiences
by: L.G. Merckel, et al.
Published: (2024-03-01)

Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT)
by: Gregor Habl, et al.
Published: (2017-05-01)

A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT)
by: Sydney Wolfe, et al.
Published: (2023-09-01)

Enhancing Androgen Deprivation Therapy (ADT) integration in prostate cancer: Insights for Stereotactic Body Radiotherapy (SBRT) and brachytherapy modalities
by: A. Gomez-Iturriaga, et al.
Published: (2024-03-01)

Feasibility of online radial magnetic resonance imaging for adaptive radiotherapy of pancreatic tumors
by: Guus Grimbergen, et al.
Published: (2023-04-01)

MR-Guided Hypofractionated Radiotherapy: Current Emerging Data and Promising Perspectives for Localized Prostate Cancer
by: Francesco Cuccia, et al.
Published: (2021-04-01)

Comparison of beam segment versus full plan re-optimization in daily magnetic resonance imaging-guided online-adaptive radiotherapy
by: Janita E. van Timmeren, et al.
Published: (2021-01-01)

Factors influencing local control after MR-guided stereotactic body radiotherapy (MRgSBRT) for adrenal metastases
by: Gamze Ugurluer, et al.
Published: (2024-05-01)

Magnetic resonance guided adaptive stereotactic body radiotherapy for lung tumors in ultracentral location: the MAGELLAN trial (ARO 2021-3)
by: Sebastian Regnery, et al.
Published: (2022-05-01)

MR-guided stereotactic radiation therapy for head and neck cancers
by: He Wang, et al.
Published: (2024-05-01)

Interfractional Geometric Variations and Dosimetric Benefits of Stereotactic MRI Guided Online Adaptive Radiotherapy (SMART) of Prostate Bed after Radical Prostatectomy: Post-Hoc Analysis of a Phase II Trial
by: Minsong Cao, et al.
Published: (2021-06-01)

Long-Term Outcomes of Stereotactic Body Radiotherapy (SBRT) for Intraprostatic Relapse after Definitive Radiotherapy for Prostate Cancer: Patterns of Failure and Association between Volume of Irradiation and Late Toxicity
by: Marcin Miszczyk, et al.
Published: (2023-02-01)

1.5T MR-Guided Daily Adaptive Stereotactic Body Radiotherapy for Prostate Re-Irradiation: A Preliminary Report of Toxicity and Clinical Outcomes
by: Francesco Cuccia, et al.
Published: (2022-04-01)

Patterns of utilization and clinical adoption of 0.35 Tesla MR-guided radiation therapy in the United States – Understanding the transition to adaptive, ultra-hypofractionated treatments
by: Michael D. Chuong, et al.
Published: (2023-01-01)

MR-Guided Adaptive Radiotherapy for Bladder Cancer
by: Adham Hijab, et al.
Published: (2021-02-01)

Are liver contour and bone fusion comparable to fiducials for IGRT in liver SBRT?
by: C. de la Pinta, et al.
Published: (2023-09-01)

Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER)
by: Ariel E. Marciscano, et al.
Published: (2023-08-01)

First Experience and Prospective Evaluation on Feasibility and Acute Toxicity of Online Adaptive Radiotherapy of the Prostate Bed as Salvage Treatment in Patients with Biochemically Recurrent Prostate Cancer on a 1.5T MR-Linac
by: Daniel Wegener, et al.
Published: (2022-08-01)

Initial Clinical Experience of MR-Guided Radiotherapy for Non-Small Cell Lung Cancer
by: Cathryn B. Crockett, et al.
Published: (2021-03-01)

Feasibility of tumour-focused adaptive radiotherapy for bladder cancer on the MR-linac
by: A. Mitchell, et al.
Published: (2022-07-01)

Focal salvage treatment for radiorecurrent prostate cancer: A magnetic resonance-guided stereotactic body radiotherapy versus high-dose-rate brachytherapy planning study
by: Thomas Willigenburg, et al.
Published: (2020-07-01)

Prognostic utility of biopsy-based PTEN and ERG status on biochemical progression and overall survival after SBRT for localized prostate cancer
by: Michael C. Repka, et al.
Published: (2024-03-01)

MRI-Guided Radiotherapy for Prostate Cancer: a New Paradigm
by: Jure Murgić, et al.
Published: (2022-01-01)

In regard to Cuccia et al.: impact of hydrogel peri-rectal spacer insertion on prostate gland intra-fraction motion during 1.5 T MR-guided stereotactic body radiotherapy
by: Hamed Ghaffari, et al.
Published: (2020-08-01)